The Emirati Genome Project aims to sequence one million genomes, thereby improving disease understanding and advancing precision medicine.

The partnership will also explore research and development collaborations with global academic institutions to further biotechnology initiatives in Abu Dhabi.

This collaboration was unveiled during the Abu Dhabi Global Health Week, where M42 is recognized as a Foundational Partner.

Juvenescence, co-founded by Jim Mellon, is backed by a leadership team with extensive experience in drug discovery, having previously facilitated significant biopharma deals totaling $30 billion in peak annual sales.

M42's infrastructure, which includes the Emirati Genome Project and Abu Dhabi Biobank, supports drug discovery and precision medicine, enhancing its biotechnology strategy in the region.

M42 and Juvenescence have announced a strategic partnership aimed at enhancing life sciences research by leveraging M42's expertise in genomics and clinical trials alongside Juvenescence's AI technology and drug development experience.

Hasan Jasem Al Nowais, M42's Managing Director, highlighted the partnership's significance in reinforcing Abu Dhabi's role as a global hub for AI-driven therapeutics and biomedical innovation.

The partnership seeks to develop a pipeline of innovative medicines targeting age-related diseases and addressing high unmet health needs both in the UAE and worldwide.

This initiative is particularly timely as it addresses the rising prevalence of age-related conditions, such as cardiovascular disease and neurodegeneration, in light of increasing global life expectancy.

The collaboration signifies a shift in healthcare focus from merely treating diseases to proactively addressing the biology of aging.

Dr. Richard Marshall from Juvenescence noted that this partnership will facilitate the development of a unique pipeline of therapeutics aimed at improving global health spans.

This collaboration is part of a series B-1 fundraise focused on developing AI-enabled therapeutics for age-related diseases.